Xanthopoulos Kleanthis G

Avg. Two Year Performance

(51%) Avg. Purchase Return
(23%) Compound
88% Avg. Sale Return
37% Compound
1 Mo3 Mo6 Mo1 Yr2 Yr
Average Purchase Return(23%)(34%)58%(11%)(51%)
Purchase Success Rate1 of 20 of 21 of 21 of 20 of 2
Average Sale Return12%29%49%58%88%
Sale Success Rate16 of 2918 of 2916 of 2919 of 2928 of 29

Regulus Therapeutics Inc.

Drugs » Drug Manufacturers - Major

President and CEO, Director:

Holdings: 83.92K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--

ISIS Pharmaceuticals Inc.

Drugs » Drug Manufacturers - Other

President of Regulus:

Holdings: shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--

NexMed Inc.

Drugs » Drug Manufacturers - Other

Director:

Holdings: 24.57K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--

Anadys Pharmaceuticals Inc.

Drugs » Biotechnology

Director:

Holdings: 184.54K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--

Zosano Pharma Corp

Drugs » Biotechnology

Director:

Holdings: 23.6K shares

Sentiment

Insider Trading Sentiment: Hold

Avg. Two Year Performance

No purchase track record
No sale track record

Last Three Months:

0 Net Amount
Buy:0--
Sell:0--